On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 1-27

  Atassi, M Zouhair ^a   Oshima, Minako ^a   Deitiker, Philip ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Antigen mimicry; Antigen presentation; Autoimmune disease; Immunotherapy; MHC; Microbial antigens; Myasthenia gravis; Synthetic peptides

Indexed keywords

BACTERIAL ANTIGEN; CHOLINERGIC RECEPTOR; EPITOPE; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; CROSS REACTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; AUTOANTIBODIES; B-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; PEPTIDE FRAGMENTS; RECEPTORS, CHOLINERGIC;

EID: 0034788256     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (95)

1. Acetylcholine receptor antibodies in myasthenia gravis
2. Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptor is under H-2-linked Ir gene control
3. Molecular properties of nicotinic acetylcholine receptors
4. Acetylcholine receptor: An allosteric protein
5. Primary structure of α-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence
6. Primary structures of β- and δ-subunit precursors of Torpedo californica acetylcholine receptor deducet from cDNA sequences
7. Structural homology of Torpedo californica acetylcholine receptor subunits
8. Nucleotide and deduced amino acid sequences of Torpedo californica acetylcholine receptor γ subunit
9. Nucleotide sequence of the mouse muscle nicotinic acetylcholine receptor α subunit
10. Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor α-subunit
11. A universal oligonudeotide probe for acetylcholine receptor genes: Selection and sequencing of cDNA clones of the mouse muscle β subunit
12. Mouse nicotinic acetylcholine receptor γ subunit: cDNA sequence and gene expression
13. Isolation and characterization of a cDNA clone for the complete protein coding region of the δ subunit of the mouse acetylcholine receptor
14. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of musde acetylcholine receptor
15. Nucleotide sequence of human muscle acetylcholine receptor β-subunit
16. Primary structure of the human muscle acetylcholine receptor cDNA cloning of the γ and ε subunits
17. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671
18. Primary structure of γ subunit precursor of calf-musde acetylcholine receptor deduced from the cDNA sequence
19. Large-scale purification of the acetylcholine-receptor protein in its membrane-bound and detergent-extracted forms from Torpedo marmorata electric organ
20. High affinity binding of α bungarotoxin to the purified α subunit and its 27,000 dalton proteolytic peptide from Torpedo marmorata acetylcholine receptor. Requirements for sodium dodecyl sulfate
21. Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor
22. Recent advances in chemistry and pharmacology of snake toxins
23. 125I-α-bungarotoxin binding activity to the α-subunit of Torpedo acetylcholine receptor isolated by gel electrophoresis in sodium dodecyl sulfate
24. α-neurotoxin binding to acetylcholine receptor: Localization of the full profile of the cobratoxin-binding regions in the α-chain of Torpedo californica acetylcholine receptor by a comprehensive synthetic strategy
25. Profile of the α-bungarotoxin-binding regions on the extracellular part of the α-chain of Torpedo californica acetylcholine receptor
26. The regions of α-neurotoxin binding on the extracellular part of the α-subunit of human acetylcholine receptor
27. Localization of the functional sites on the α subunit of acetylcholine receptor and the receptor sites on α-neurotoxin
28. The short-neurotoxin binding regions on the α-chain of human and Torpedo californica acetylcholine receptors
29. Region of peptide 125-147 of acetylcholine receptor α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity and modulating autoantibodies
30. Localization of the functional sites on the α chain of acetylcholine receptor
31. Profile of the continuous antigenic regions on the extracellular part of the α chain of an acetylcholine receptor
32. Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors
33. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value
34. Strain differences in the autoimmune response of mice to acetylcholine receptors
35. HLA-A, -B, -C and -D antigens in male patients with myasthenia gravis
36. HLA-DQ beta-chain polymorphism linked to myastenia gravis
37. Immunogenetics of experimental autoimmune myasthenia gravis
38. A novel and comprehensive synthetic approach for the elucidation of protein antigenic sites. Determination of the antigenic profile of the α-chain of human hemoglobin
39. Autoimmune T cell recognition of human acetylcholine receptor: The sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit
40. Profile of the regions on the α-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis
41. T lymphocyte recognition of acetylcholine receptor: Localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor
42. An immunodominant site of acetylcholine receptor in experimental myasthenia gravis mapped with T lymphocyte clones and synthetic peptides
43. Profile of the regions of acetylcholine receptor α chain recognized by T lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor
44. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor
45. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by an monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide
46. The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice
47. b gene and protects C57BL/10 mice from developing autoimmune myasthenia gravis
48. bm12 gene is evidence for genetic exchange between mouse immune response genes
49. bm12 mutation using site-directed mutagenesis and DNA-mediated gene transfer
50. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
51. b on binding with and antigen presentation of Torpedo acetylcholine receptor α-chain peptide 146-162
52. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines
53. Analysis of helper-T-cell function by acetylcholine receptor reactive cell lines of defined AChR-subunit specificity
54. Molecular recognition of acetylcholine receptor. Recognition by α-neurotoxins and by immune and autoimmune responses and manipulation of the responses
55. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors
56. Production of anti-acetylcholine receptor-α antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: Role of immunoregulatory T cells and monocytes
57. B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica nicotinic acetylcholine receptor
58. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of myasthenia gravis?
59. Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins
60. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites
61. The H-2 major histocompatibility complex and the I immune response region. Genetic variation, function and organization
62. Genetic control of the immune response to hen's egg-white lysozyme in mice. I. Antibody and T-lymphocyte proliferative responses to the native protein
63. Genetic control of immune response to sperm whale myoglobin in mice. I. T-lymphocyte proliferative response under H-2 linked Ir gene control
64. Genetic control of T-lymphocyte proliferative responses to sperm whale myoglobin and its synthetic antigenic sites in mice
65. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites
66. Genetic control and intersite influences on the immune response to sperm whale myoglobin
67. Immunotherapy in neuromuscular disorders: Current and future strategies
68. The relationship of age to outcome in myasthenia gravis
69. T lymphocyte recognition of sperm whale myoglobin: Specificity of T cell recognition following neonatal tolerance with either myoglobin or synthetic peptides of an antigenic site
70. Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin
71. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase
72. Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates to peptides
73. T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses
74. Selective immunosuppression
75. Prospects for specific immunotherapy in myasthenia gravis
76. Different HLA-DQ are positively and negatively associated in Swedish patients with myasthenia gravis
77. A novel HLA-DR4 allele (DRB1*0414) in a patient with myasthenia gravis
78. HLA-DPB1 allele associates with early-onset myasthenia gravis in Japan
79. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: Positioning of T-cell receptors on HLA-DR2/peptide complexes
80. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide
81. A synthetic peptide from the third hypervariable region of major histocompatibility complex class II β-chain as a vaccine for treatment of experimental autoimmune encephalomyelitis
82. Pocket 4 of the HLA-DR (αβ1*0401) molecule is a major determinant of T cell recognition of peptide
83. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides
84. T-cell recognition of proteins: Conclusions from the localization of the full T-cell recognition profiles of two native proteins
85. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin
86. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor
87. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis
88. Immunotherapy for myasthenia gravis: A murine model
89. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis
90. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T cell epitope
91. Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-Aβ cDNA clones
92. Acetylcholine receptor-α-bungarotoxin interactions: Determination of the region-to-region contacts by peptide-peptide interactions and molecular modeling of the receptor cavity
93. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis
94. Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis
95. Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan